Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 21, 2017)
  • 8-K (Nov 7, 2017)
  • 8-K (Oct 24, 2017)
  • 8-K (Jul 25, 2017)
  • 8-K (Jun 13, 2017)
  • 8-K (Jun 9, 2017)

 
Other

Biogen Idec 8-K 2005

Documents found in this filing:

  1. 8-K
  2. Ex-10.1
  3. Graphic
  4. Graphic
  5. Graphic
e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report:
September 12, 2005
(Date of earliest event reported)
Biogen Idec Inc.
(Exact name of Registrant as specified in its Charter)
         
Delaware   0-19311   33-0112644
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer Identification No.)
14 Cambridge Center
Cambridge, Massachusetts 02141

(Address of principal executive offices, including zip code)
(617) 679-2000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


Table of Contents


Table of Contents

Item 1.01 — Entry into a Material Definitive Agreement
     On September 12, 2005, the Compensation and Management Development Committee of the Company’s Board of Directors (the “Compensation Committee”) approved the grant of an aggregate of approximately 1.17 million performance-based restricted stock units to be settled in shares of the Company’s common stock to a group of approximately 200 of the Company’s employees at the director-level and above. The grants were made under the Company’s 2005 Omnibus Equity Plan. Grants were made to all of the Company’s executive officers other than James C. Mullen, the Company’s Chief Executive Officer and President, and William H. Rastetter, the Company’s Executive Chairman.
     The grants to executive officers are as follows: Raymond G. Arner, Acting General Counsel (30,000 units); Burt A. Adelman, Executive Vice President, Development (45,000 units); John M. Dunn, Executive Vice President, New Ventures (29,500 units); Peter N. Kellogg, Executive Vice President, Finance and Chief Financial Officer (50,000 units); Connie L. Matsui, Executive Vice President, Corporate Strategy and Communications (25,000 units); Craig E. Schneier, Executive Vice President, Human Resources (45,000 units); and Mark C. Wiggins, Executive Vice President, Business Development (40,000 units).
     These restricted stock units have performance-based vesting that will depend entirely upon the Company’s achievement, over the next 12-18 months, of certain performance-based objectives approved by the Compensation Committee, and continued employment.
     A form of the grant notice utilized in connection with these grants is attached hereto as Exhibit 10.1.

 


Table of Contents

Item 9.01 — Financial Statements and Exhibits
     
Exhibit    
Number   Description
   
 
10.1   
Form of Grant Notice (Restricted Stock Units)

 


Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 15, 2005
         
    BIOGEN IDEC INC.
 
 
       
 
  By:   /s/ Raymond G. Arner
 
       
 
  Name:   Raymond G. Arner
 
       
 
  Title:   Acting General Counsel 
 
       

 


Table of Contents

Exhibit Index
     
Exhibit    
Number   Description
   
 
10.1   
Form of Grant Notice (Restricted Stock Units)

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki